USRE50453EExpiredUtility

Indole derivatives as CFTR modulators

73
Assignee: VERTEX PHARMAPriority: Apr 7, 2006Filed: Dec 28, 2022Granted: Jun 10, 2025
Est. expiryApr 7, 2026(expired)· nominal 20-yr term from priority
Inventors:Sara S. Hadida RuahPeter Diederik Jan GrootenhuisFredrick Van GoorJinglan ZhouBrian BearMark MillerJason MccartneyMehdi Michel Djamel NumaXiaoqing Yang
A61K 45/06A61K 31/405C07D 403/12A61K 31/47C07D 405/14A61K 31/454C07D 405/12C07D 487/04G01N 33/5035A61K 31/5377A61K 31/4192C07D 471/04G01N 2333/705C07D 233/64A61K 31/407C07D 209/08A61K 31/404A61K 31/4045A61K 31/4184G01N 2500/10A61K 31/41
73
PatentIndex Score
0
Cited by
589
References
3
Claims

Abstract

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Claims

exact text as granted — not AI-modified
We claim: 
     
       1. A compound of formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
       2. A pharmaceutical composition comprising
 (i) a compound of formula: 
 
       
         
           
           
               
               
           
         
         (ii) a pharmaceutically acceptable carrier. 
       
     
     
       3. The composition of  claim 2 , further comprising an additional agent wherein the additional agent is N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.